SOD1 Plasma Level as a Biomarker for Therapeutic Failure in Cutaneous Leishmaniasis

Here we show that increased plasma SOD1 level significantly predicts therapeutic failure to pentavalent antimony in cutaneous leishmaniasis caused by Leishmania braziliensis. In Leishmania amazonensis-infected patients, host SOD1 levels discriminate between localized and drug-resistant diffuse cutaneous leishmaniasis. Using in situ transcriptomics (nCounter), we demonstrate a significant positive correlation between host SOD1 and IFN-alpha/beta mRNAs, as well as interkingdom correlation between host SOD1 and parasite SOD2/4 mRNAs. In human macrophages, SOD1 in vitro treatment increases parasite burden and induces diffuse cutaneous leishmaniasis-like morphology. Thus, SOD1 is a clinically relevant biomarker and a therapeutic target in both localized and diffuse cutaneous leishmaniasis.

Jaar van publicatie:2014

BOF-keylabel:ja

IOF-keylabel:ja

BOF-publication weight:6

CSS-citation score:1

Auteurs:International

Authors from:Higher Education

Toegankelijkheid:Open